Public Citizen sent a petition to the Food and Drug Administration saying the risks of Victoza far outweigh its benefits as a diabetes drug, a crowded field that includes nearly a dozen similar medications.
The group notes that FDA approved the drug in 2010 against the recommendation of three staff scientists.
“The need for new therapies for Type 2 diabetes is not so urgent that
one must tolerate a significant degree of uncertainty regarding serious
risk concerns,” wrote reviewer Dr. Karen Mahoney, in an agency memo
obtained by Public Citizen.